Thyroid cancer

Maria E. Cabanillas, David G. McFadden, Cosimo Durante

Research output: Contribution to journalReview article

248 Scopus citations

Abstract

Thyroid cancer is the fifth most common cancer in women in the USA, and an estimated over 62 000 new cases occurred in men and women in 2015. The incidence continues to rise worldwide. Differentiated thyroid cancer is the most frequent subtype of thyroid cancer and in most patients the standard treatment (surgery followed by either radioactive iodine or observation) is effective. Patients with other, more rare subtypes of thyroid cancer—medullary and anaplastic—are ideally treated by physicians with experience managing these malignancies. Targeted treatments that are approved for differentiated and medullary thyroid cancers have prolonged progression-free survival, but these drugs are not curative and therefore are reserved for patients with progressive or symptomatic disease.

Original languageEnglish (US)
Pages (from-to)2783-2795
Number of pages13
JournalThe Lancet
Volume388
Issue number10061
DOIs
StatePublished - Dec 3 2016

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Thyroid cancer'. Together they form a unique fingerprint.

  • Cite this

    Cabanillas, M. E., McFadden, D. G., & Durante, C. (2016). Thyroid cancer. The Lancet, 388(10061), 2783-2795. https://doi.org/10.1016/S0140-6736(16)30172-6